Abstract:BACKGROUND Cardiac troponin provides diagnostic and prognostic information in acute coronary syndromes, but its role in acute decompensated heart failure is unclear. The purpose of our study was to describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with acute decompensated heart failure. METHODS We analyzed hospitalizations for acute decompensated heart failure between October 2001 and January 2004 that were recorded in the Acute Decompensated Heart Failure National Registry (ADHERE). Entry criteria included a troponin level that was obtained at the time of hospitalization in patients with a serum creatinine level of less than 2.0 mg per deciliter (177 micromol per liter). A positive troponin test was defined as a cardiac troponin I level of 1.0 microg per liter or higher or a cardiac troponin T level of 0.1 microg per liter or higher. RESULTS Troponin was measured at the time of admission in 84,872 of 105,388 patients (80.5%) who were hospitalized for acute decompensated heart failure. Of these patients, 67,924 had a creatinine level of less than 2.0 mg per deciliter. Cardiac troponin I was measured in 61,379 patients, and cardiac troponin T in 7880 patients (both proteins were measured in 1335 patients). Overall, 4240 patients (6.2%) were positive for troponin. Patients who were positive for troponin had lower systolic blood pressure on admission, a lower ejection fraction, and higher in-hospital mortality (8.0% vs. 2.7%, P<0.001) than those who were negative for troponin. The adjusted odds ratio for death in the group of patients with a positive troponin test was 2.55 (95% confidence interval, 2.24 to 2.89; P<0.001 by the Wald test). CONCLUSIONS In patients with acute decompensated heart failure, a positive cardiac troponin test is associated with higher in-hospital mortality, independently of other predictive variables. (ClinicalTrials.gov number, NCT00366639 [ClinicalTrials.gov].).

A Novel Method for Detecting Mutation of Mitochondrial DNA in Tumor Cells by Next Generation Sequencing

Next Generation Sequencing Technology and Its Application in Detecting Gene Mutations

Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

A Cost-Efficient Method for Sequencing the Human Whole Mitochondrial Genome Utilizing Multiplex PCR-based Next Generation Sequencing

Cardiac troponin and outcome in acute heart failure.

Somatic Mutation Detection in Complete Mitochondrial DNA of Lung Cancer Patients

Postmenopausal sexuality in Thai women.

Characterization of long-term cultures of hepatitis C virus

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Mitosomatic: a Tool for Accurate Identification of Mitochondrial DNA Somatic Mutations Without Paired Controls

Detection of ultra-rare mutations by next-generation sequencing

Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing

Single molecule targeted sequencing for cancer gene mutation detection

Mitodataclean: A Machine Learning Approach for the Accurate Identification of Cross‐contamination‐derived Tumor Mitochondrial DNA Mutations

Detection of Mitochondrial Mutations Through Isothermal Nucleic Acid Amplification Coupled With Clustered Regularly Interspaced Short Palindromic Repeat-Associated Endonuclease Cas13a

[Results of the repair of isolated coarctation of the aorta during the 1st 6 months of life, Apropos of 46 cases].

Approach, Application, and Bioethics of mtDNA Sequencing in Cancer.

Research progress of sequencing method for animal mitochondrial genome

Next-Generation Sequencing-Based Analysis of Urine Cell-Free mtDNA Reveals Aberrant Fragmentation and Mutation Profile in Cancer Patients

[Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].